Shuji Ikegami

This inventor holds 7 USPTO granted patents and 4 published patent applications, plus 3 CIPO patents and 5 EPO patents. Top assignees: Meiji Co., Ltd., Meiji Dairies Corporation. Active years: 2008-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shuji Ikegami. Retrieved from https://idiyas.com/inventor/shuji-ikegami-kwsgabbv

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 7 (Patent Applications = 4)

% Patents Active = 71.4

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 5

Average Co-Inventor Count = 8.7

ph-index = 3

Forward Citations = 25(Granted Patents)

Location History:

Kanagawa, JP (2009 - 2016)
Odawara, JP (2008 - 2019)

Company Filing History:

Meiji Dairies Corporation

patents

Years Active: 2008-2019

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10195271 - Antibody titer-increasing agent using lactic acid bacterium (2019-02-05),

2. 9314041 - Immune function modulating agents (2016-04-19),

3. 9095604 - Composition for preventing inflammations (2015-08-04),

4. 8110607 - Process for producing 1,4-dihydroxy-2-naphthoic acid (2012-02-07),

5. 7834061 - Process for producing 1,4-dihydroxy-2-naphthoic acid (2010-11-16),

6. 7629155 - Process for producing 1,4-dihydroxy-2-naphthoic acid (2009-12-08),

7. 7374915 - Process for producing 1,4-dihydroxy-2-naphthoic acid (2008-05-20),

Title: Shuji Ikegami: Innovating Immunology Solutions

Introduction

Shuji Ikegami, an accomplished inventor based in Kanagawa, Japan, has contributed significantly to the field of immunology through his innovative solutions. With a portfolio of 7 patents, his work addresses crucial developments in antibody enhancement and immune modulation.

Latest Patents

Among his notable inventions, Ikegami has developed an **antibody titer-increasing agent using lactic acid bacterium**. This invention aims to provide a safe, convenient, and economical adjuvant capable of sustaining the effects of vaccinations. The agent includes subspecies OLL1073R-1, which underscores its effectiveness and ease of use across all ages. Another key invention is the **immune function modulating agent**, a probiotic derived from lactobacilli isolated from human adult feces. This discovery has demonstrated remarkable capabilities in enhancing IL-12 production, balancing Th1/Th2 responses, and suppressing antigen-specific IgE production, marking a significant advancement in immune health management.

Career Highlights

Ikegami has had an impactful career with noteworthy affiliations at esteemed companies such as Meiji Co., Ltd. and Meiji Dairies Corporation. His contributions have been pivotal in advancing the applications of probiotics in enhancing immune function and vaccine efficacy.

Collaborations

Throughout his career, Shuji Ikegami has collaborated with esteemed professionals like Seiya Makino and Yoshio Sato. These partnerships have fostered a collaborative environment that has led to significant advancements in the field of immunology.

Conclusion

Shuji Ikegami exemplifies the spirit of innovation, with his inventions paving the way for breakthroughs in immunology. His patents not only reflect his dedication to scientific progress but also his commitment to improving public health outcomes through safe and effective solutions. His work continues to inspire future advancements in the field.

Profile summary based on public USPTO records.